Toleranzia AB (TOL.ST)
SEK 0.61
(0.33%)
SEK 0.61
(0.33%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.06 SEK | 26.99% |
| 2022 | -0.08 SEK | 14.11% |
| 2021 | -0.09 SEK | 47.47% |
| 2020 | -0.17 SEK | 66.67% |
| 2019 | -0.51 SEK | -27.5% |
| 2018 | -0.40 SEK | 27.27% |
| 2017 | -0.55 SEK | -19.57% |
| 2016 | -0.46 SEK | -21.05% |
| 2015 | -0.38 SEK | -479.27% |
| 2014 | -0.07 SEK | -642.15% |
| 2013 | 0.01 SEK | -6.92% |
| 2012 | 0.01 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q3 | -0.01 SEK | -74.39% |
| 2024 Q2 | -0.01 SEK | -105.0% |
| 2024 Q1 | -0.00 SEK | 58.76% |
| 2023 Q2 | -0.02 SEK | -28.98% |
| 2023 Q4 | -0.01 SEK | -1.04% |
| 2023 Q1 | -0.02 SEK | 4.86% |
| 2023 FY | - SEK | 50.72% |
| 2023 Q3 | -0.01 SEK | 57.71% |
| 2022 Q2 | -0.02 SEK | -6.91% |
| 2022 Q3 | -0.02 SEK | 4.48% |
| 2022 Q4 | -0.02 SEK | 3.65% |
| 2022 FY | - SEK | 14.11% |
| 2022 Q1 | -0.02 SEK | -20.51% |
| 2021 Q4 | -0.02 SEK | 19.59% |
| 2021 Q2 | -0.03 SEK | -10.69% |
| 2021 FY | - SEK | 47.47% |
| 2021 Q1 | -0.03 SEK | 12.37% |
| 2021 Q3 | -0.02 SEK | 33.1% |
| 2020 FY | - SEK | 66.67% |
| 2020 Q2 | -0.04 SEK | 32.0% |
| 2020 Q4 | -0.03 SEK | -52.55% |
| 2020 Q3 | -0.02 SEK | 55.66% |
| 2020 Q1 | -0.06 SEK | 50.0% |
| 2019 Q3 | -0.12 SEK | -68.07% |
| 2019 FY | - SEK | -27.5% |
| 2019 Q2 | -0.07 SEK | -18.8% |
| 2019 Q1 | -0.06 SEK | 45.36% |
| 2019 Q4 | -0.13 SEK | -8.33% |
| 2018 Q4 | -0.11 SEK | -76.57% |
| 2018 FY | - SEK | 27.27% |
| 2018 Q3 | -0.06 SEK | 22.8% |
| 2018 Q2 | -0.08 SEK | -6.32% |
| 2018 Q1 | -0.08 SEK | 52.56% |
| 2017 Q2 | -0.16 SEK | -14.29% |
| 2017 FY | - SEK | -19.57% |
| 2017 Q3 | -0.09 SEK | 42.19% |
| 2017 Q1 | -0.14 SEK | 17.65% |
| 2017 Q4 | -0.16 SEK | -72.97% |
| 2016 Q1 | -0.10 SEK | 58.33% |
| 2016 FY | - SEK | -21.05% |
| 2016 Q4 | -0.17 SEK | -79.51% |
| 2016 Q3 | -0.09 SEK | 5.3% |
| 2016 Q2 | -0.10 SEK | 0.0% |
| 2015 Q2 | -0.06 SEK | -86.18% |
| 2015 Q1 | -0.03 SEK | 55.43% |
| 2015 Q3 | -0.07 SEK | -15.9% |
| 2015 FY | - SEK | -479.27% |
| 2015 Q4 | -0.24 SEK | -265.85% |
| 2014 FY | - SEK | -642.15% |
| 2014 Q4 | -0.07 SEK | 0.0% |
| 2013 FY | - SEK | -6.92% |
| 2012 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AcuCort AB | -0.16 SEK | 65.0% |
| AlzeCure Pharma AB (publ) | -0.60 SEK | 90.667% |
| BioGaia AB (publ) | 3.62 SEK | 101.547% |
| Enzymatica AB (publ) | -0.28 SEK | 80.0% |
| Enorama Pharma AB (publ) | -1.61 SEK | 96.522% |
| Gabather AB (publ) | -0.65 SEK | 91.385% |
| Klaria Pharma Holding AB (publ.) | -0.36 SEK | 84.444% |
| Moberg Pharma AB (publ) | -1.33 SEK | 95.789% |
| Nanexa AB (publ) | -1.09 SEK | 94.862% |
| Newbury Pharmaceuticals AB (publ) | -0.72 SEK | 92.222% |
| ODI Pharma AB | 0.02 SEK | 339.316% |
| Orexo AB (publ) | -3.73 SEK | 98.499% |
| Probi AB (publ) | 1.48 SEK | 103.784% |
| Swedencare AB (publ) | 0.37 SEK | 115.135% |
| Swedish Orphan Biovitrum AB (publ) | 7.47 SEK | 100.75% |
| Vivesto AB | -0.74 SEK | 92.432% |